Peripheral alpha 2-adrenergic antagonist vatinoxan improves the quality of medetomidine–midazolam sedation in Wistar rats
Veterinary Anaesthesia and Analgesia · 2025
DOI: 10.1016/j.vaa.2025.04.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary Anaesthesia and Analgesia, 2025. Verfasst von Emily Lindh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland. Electronic address: emily.…. Hauptthemen laut MEDLINE: Medetomidine, Midazolam, Hypnotics and Sedatives, Adrenergic alpha-2 Receptor Antagonists. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vetcare Oy, Suomen Eläinlääketieteen Säätiö.
Abstract (Originalsprache)
OBJECTIVE: To evaluate the effects of a peripheral alpha 2-adrenoceptor antagonist, vatinoxan, on medetomidine-midazolam sedation in adult Wistar rats. STUDY DESIGN: Randomized, blinded, crossover study (7 day rest period between treatments). ANIMALS: A group of 10 male adult Wistar rats weighing 311-332 g. METHODS: Rats were administered four subcutaneous (SC) treatments: medetomidine 0.25 mg kg-1 and midazolam 2 mg kg-1 (MM), medetomidine 0.125 mg kg-1 and midazolam 1 mg kg-1 (½MM), MM + vatinoxan 5 mg kg-1 (MMV) or ½MM + vatinoxan 2.5 mg kg-1 (½MMV). The time to loss of consciousness was determined by measuring the time to loss of the righting reflex. Noninvasive mean arterial blood pressure (MAP) and pulse rate were measured. After 55 minutes, blood glucose concentration (BGC) was analysed and atipamezole (1.25 mg kg-1 or 0.625 mg kg-1) and flumazenil (0.2 mg kg-1) were injected SC. RESULTS: The time to loss of consciousness (seconds) was significantly shorter after MMV [152 (122-189)] [median (range)] than after MM [172 (108-325)] or ½MM [243 (140-508)] (p = 0.050, p = 0.001). BGC (mmol L-1) was significantly lower after MMV (9.6 ± 1.8, mean ± standard deviation) and ½MMV (9.7 ± 1.8) than after MM (18.1 ± 4.1) or ½MM (17.3 ± 2.4) (all p < 0.001). No mortality, hypotension (MAP < 60 mmHg) or hypoglycaemia (BCG < 4.0) were detected after any treatment. CONCLUSIONS AND CLINICAL RELEVANCE: By mitigating the medetomidine-associated effects outside of the central nervous system and reducing the time to loss of consciousness, vatinoxan improved the quality of SC medetomidine-midazolam sedation in laboratory rats.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland. Electronic address: emily.lindh@helsinki.fi.
- Laboratory Animal Centre, HiLIFE Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
- Department of Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
- Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.
Förderung
- Vetcare Oy
- Suomen Eläinlääketieteen Säätiö
Zitieren
APA
Lindh, E., Meller, A., Alm, K., Finckenberg, P., Raekallio, M., & Honkavaara, J. (2025). Peripheral alpha 2-adrenergic antagonist vatinoxan improves the quality of medetomidine–midazolam sedation in Wistar rats. Veterinary Anaesthesia and Analgesia. https://doi.org/10.1016/j.vaa.2025.04.002
Vancouver
Lindh E, Meller A, Alm K, Finckenberg P, Raekallio M, Honkavaara J. Peripheral alpha 2-adrenergic antagonist vatinoxan improves the quality of medetomidine–midazolam sedation in Wistar rats. Veterinary Anaesthesia and Analgesia. 2025. doi:10.1016/j.vaa.2025.04.002
BibTeX
@article{Lindh2025,
author = {Lindh, Emily and Meller, Anna and Alm, Karoliina and Finckenberg, Piet and Raekallio, Marja and Honkavaara, Juhana},
title = {Peripheral alpha 2-adrenergic antagonist vatinoxan improves the quality of medetomidine–midazolam sedation in Wistar rats},
journal = {Veterinary Anaesthesia and Analgesia},
year = {2025},
doi = {10.1016/j.vaa.2025.04.002}
}
EUVIMED